Media coverage about Dr. Reddy’s Laboratories (NYSE:RDY) has been trending somewhat positive this week, according to Accern Sentiment Analysis. The research firm scores the sentiment of press coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Dr. Reddy’s Laboratories earned a media sentiment score of 0.22 on Accern’s scale. Accern also gave news stories about the company an impact score of 47.9195532868062 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

Here are some of the media headlines that may have effected Accern’s analysis:

A number of research analysts recently issued reports on RDY shares. Zacks Investment Research upgraded Dr. Reddy’s Laboratories from a “sell” rating to a “hold” rating in a report on Monday, April 2nd. ValuEngine upgraded Dr. Reddy’s Laboratories from a “sell” rating to a “hold” rating in a research note on Monday, April 2nd. Two analysts have rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and an average target price of $30.51.

Dr. Reddy’s Laboratories opened at $29.24 on Thursday, reports. Dr. Reddy’s Laboratories has a 1-year low of $29.43 and a 1-year high of $29.64. The company has a debt-to-equity ratio of 0.20, a quick ratio of 1.13 and a current ratio of 1.50. The firm has a market capitalization of $5.00 billion, a price-to-earnings ratio of 26.34 and a beta of 0.25.

About Dr. Reddy’s Laboratories

Dr. Reddy's Laboratories Limited operates as an integrated pharmaceutical company worldwide. It operates through three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosage with therapeutic equivalence to branded formulations.

Insider Buying and Selling by Quarter for Dr. Reddy`s Laboratories (NYSE:RDY)

Receive News & Ratings for Dr. Reddy's Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dr. Reddy's Laboratories and related companies with's FREE daily email newsletter.